secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001517022-24-000029
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia reports Q4 2023 net income $0.6M, Auryxia $53.2M; vadadustat PDUFA Mar 27
--------------------------------------------------------------------------------

- Net income of $0.6M in Q4 2023 vs net loss $6.1M a year ago; full-year net income $51.9M vs loss $94.2M in 2022.
- Auryxia net product revenue $53.2M in Q4, $170.3M full year, within guidance of $170-175M.
- Vadadustat PDUFA date March 27, 2024; Akebia preparing for potential U.S. launch.
- Closed $55M BlackRock term loan and raised $26M via ATM; cash $42.9M at year-end, sufficient for 24 months if vadadustat approved.
- Appointed Nicholas Grund as Chief Commercial Officer; introduced early-stage pipeline programs AKB-9090 and AKB-10108.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000029/0001517022-24-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000029/akba-20240314.htm
  HTML page:      https://secwatch.observer/filing/0001517022-24-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer